Representative Publications & Presentations Include:

  • “FDA Opens Useful Dialogue on Orange Book Patent Listings,” co-author, Law360, June 18, 2020.
  • “Inequitable Conduct Accusations Still Powerful Pharma Patent Tool Post-Therasense,” Jason Lief, Bloomberg Law: INSIGHT, July 17, 2019.
  • “Venue Menu: Should Litigants be Concerned about the Venue in a Hatch-Waxman Case,” Jason Lief, Intellectual Property Magazine, July/August 2018 at 43-44.
  • “Panel: Hatch-Waxman Cases and Inter Partes Reviews,” Jason Lief, Panel Chair, 2018 BIO International Conference in Boston (quoted in the June 6, 2018 Life Sciences Intellectual Property Review article “Former Judge Weighs in on Differing Patent Standards”).
  • “The Fate of Pharma Patents in U.S. Inter Partes Review Proceedings,” Jason Lief et al., LawyerIssue, November 8, 2016.
  • “The PTO Versus the Courts: Who Rules and What are the Rules in Parallel Patent Proceedings,” Jason Lief, Chapter in Practicing Law Institute’s 2010 “Reissue and Reexamination Strategies and Tactics with Concurrent Litigation”.
  • “Pharmaceutical Patents After KSR: What is Not Obvious?,” Jason Lief and Peter Schuyler, Journal of Commercial Biotechnology, January 2009, Volume 15, Issue 1, pp 44–58.
  • “MedImmune’s Effect on Declaratory Judgment Jurisdiction in Pharmaceutical and Hatch-Waxman Litigations,” Jason Lief, 147 Intellectual Property Counselor Article II, March 2009.
  • “Revising the Patent System,” Letter to Editor, Jason Lief, Chemical & Eng’g News, Vol. 85, Issue 46, p. 5 (Nov. 12, 2007).
  • “Constitution Provides No Right To Be Killed,” Jason Lief, Nat’l L.J., Aug. 26, 1996, at A20.
  • “Insuring Domestic Tranquility Through Quieter Products: A Proposed Product-Nuisance Tort,” Jason Lief, 16 Cardozo L. Rev. 595 (Dec. 1994).